Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?

Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?

Background and purpose: Optimal treatment duration is unknown in metastatic renal cell carcinoma (mRCC) responding to immune checkpoint inhibitors (ICPIs). Prolonged treatment can lead to late toxicity, burden for day clinics and financial impact. Patients and methods: This multicenter retrospectiv...

Full description

Saved in:
Bibliographic Details
Main Authors: Alexander Decruyenaere, Gennigens Christine, Rottey Sylvie, Laenen Annouschka, Emmanuel Seront, Els Everaert, Philip R Debruyne, Heidi Van Den Bulck, Julie Bastin, Verbiest Annelies, Christof Vulsteke, Peter Schatteman, Daisy Luyten, Sandrine Aspeslagh, Nieves Martinez-Chanza, Marlies De Bock, Thomas Meyskens, Jolanda Verheezen, Barbara Brouwers, Benoit Beuselinck
Format: Article
Language:English
Published: Medical Journals Sweden 2025-07-01
Series:Acta Oncologica
Subjects:
Renal cell carcinoma
immune checkpoint inhibitors
optimal treatment duration
treatment discontinuation
Online Access:https://medicaljournalssweden.se/actaoncologica/article/view/43876
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://medicaljournalssweden.se/actaoncologica/article/view/43876

Similar Items